666 Safety, efficacy, and biomarker results of SRK-181, a latent TGFβ1 inhibitor, in anti-PD-1 resistant metastatic ccRCC patients
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2023-11-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| _version_ | 1827766119048413184 |
|---|---|
| author | Minal Barve Ahmad A Tarhini Deepak Kilari Rana Mckay Randy Sweis Timothy Yap Justin Gainor Raghad Karim Lu Gan Lan Liu David Park Ulka N Vaishampayan Amna Sher Sunil Babu Yawen Ju Susan Henry |
| author_facet | Minal Barve Ahmad A Tarhini Deepak Kilari Rana Mckay Randy Sweis Timothy Yap Justin Gainor Raghad Karim Lu Gan Lan Liu David Park Ulka N Vaishampayan Amna Sher Sunil Babu Yawen Ju Susan Henry |
| author_sort | Minal Barve |
| collection | DOAJ |
| first_indexed | 2024-03-11T11:37:27Z |
| format | Article |
| id | doaj.art-3c77a423bbef4fbaa401cdfddf2abaff |
| institution | Directory Open Access Journal |
| issn | 2051-1426 |
| language | English |
| last_indexed | 2024-03-11T11:37:27Z |
| publishDate | 2023-11-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj.art-3c77a423bbef4fbaa401cdfddf2abaff2023-11-10T12:30:07ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262023-11-0111Suppl 110.1136/jitc-2023-SITC2023.0666666 Safety, efficacy, and biomarker results of SRK-181, a latent TGFβ1 inhibitor, in anti-PD-1 resistant metastatic ccRCC patientsMinal Barve0Ahmad A Tarhini1Deepak Kilari2Rana Mckay3Randy Sweis4Timothy Yap5Justin Gainor6Raghad Karim7Lu Gan8Lan Liu9David Park10Ulka N Vaishampayan11Amna Sher12Sunil Babu13Yawen Ju14Susan Henry153Mary Crowley Cancer Research Center, Dallas, TX, USA1H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA3Medical College of Wisconsin, Milwaukee, WI, USA12Moores Cancer Center, University of California San Diego, La Jolla, CA, USA8University of Chicago, Chicago, IL, USA7The University of Texas, Houston, TX, USADepartment of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA3NEXT Oncology, San Antonio, TX, USA1Scholar Rock, Cambridge, MA, USADepartment of Radiology, Jiangxi Cancer Hospital, Nanchang, People`s Republic of China2St Jude Crosson Cancer Institute, Fullerton, CA, USA8Division of Hematology/Oncology, University of Michigan, Ann Arbor, MI, USA9Stony Brook University, Stony Brook, NY, USA11Fort Wayne Medical Oncology Hematology Inc, Fort Wayne, IN, USA13Scholar Rock, Inc., Cambridge, MA, USA13Scholar Rock, Inc., Cambridge, MA, USA |
| spellingShingle | Minal Barve Ahmad A Tarhini Deepak Kilari Rana Mckay Randy Sweis Timothy Yap Justin Gainor Raghad Karim Lu Gan Lan Liu David Park Ulka N Vaishampayan Amna Sher Sunil Babu Yawen Ju Susan Henry 666 Safety, efficacy, and biomarker results of SRK-181, a latent TGFβ1 inhibitor, in anti-PD-1 resistant metastatic ccRCC patients Journal for ImmunoTherapy of Cancer |
| title | 666 Safety, efficacy, and biomarker results of SRK-181, a latent TGFβ1 inhibitor, in anti-PD-1 resistant metastatic ccRCC patients |
| title_full | 666 Safety, efficacy, and biomarker results of SRK-181, a latent TGFβ1 inhibitor, in anti-PD-1 resistant metastatic ccRCC patients |
| title_fullStr | 666 Safety, efficacy, and biomarker results of SRK-181, a latent TGFβ1 inhibitor, in anti-PD-1 resistant metastatic ccRCC patients |
| title_full_unstemmed | 666 Safety, efficacy, and biomarker results of SRK-181, a latent TGFβ1 inhibitor, in anti-PD-1 resistant metastatic ccRCC patients |
| title_short | 666 Safety, efficacy, and biomarker results of SRK-181, a latent TGFβ1 inhibitor, in anti-PD-1 resistant metastatic ccRCC patients |
| title_sort | 666 safety efficacy and biomarker results of srk 181 a latent tgfβ1 inhibitor in anti pd 1 resistant metastatic ccrcc patients |
| work_keys_str_mv | AT minalbarve 666safetyefficacyandbiomarkerresultsofsrk181alatenttgfb1inhibitorinantipd1resistantmetastaticccrccpatients AT ahmadatarhini 666safetyefficacyandbiomarkerresultsofsrk181alatenttgfb1inhibitorinantipd1resistantmetastaticccrccpatients AT deepakkilari 666safetyefficacyandbiomarkerresultsofsrk181alatenttgfb1inhibitorinantipd1resistantmetastaticccrccpatients AT ranamckay 666safetyefficacyandbiomarkerresultsofsrk181alatenttgfb1inhibitorinantipd1resistantmetastaticccrccpatients AT randysweis 666safetyefficacyandbiomarkerresultsofsrk181alatenttgfb1inhibitorinantipd1resistantmetastaticccrccpatients AT timothyyap 666safetyefficacyandbiomarkerresultsofsrk181alatenttgfb1inhibitorinantipd1resistantmetastaticccrccpatients AT justingainor 666safetyefficacyandbiomarkerresultsofsrk181alatenttgfb1inhibitorinantipd1resistantmetastaticccrccpatients AT raghadkarim 666safetyefficacyandbiomarkerresultsofsrk181alatenttgfb1inhibitorinantipd1resistantmetastaticccrccpatients AT lugan 666safetyefficacyandbiomarkerresultsofsrk181alatenttgfb1inhibitorinantipd1resistantmetastaticccrccpatients AT lanliu 666safetyefficacyandbiomarkerresultsofsrk181alatenttgfb1inhibitorinantipd1resistantmetastaticccrccpatients AT davidpark 666safetyefficacyandbiomarkerresultsofsrk181alatenttgfb1inhibitorinantipd1resistantmetastaticccrccpatients AT ulkanvaishampayan 666safetyefficacyandbiomarkerresultsofsrk181alatenttgfb1inhibitorinantipd1resistantmetastaticccrccpatients AT amnasher 666safetyefficacyandbiomarkerresultsofsrk181alatenttgfb1inhibitorinantipd1resistantmetastaticccrccpatients AT sunilbabu 666safetyefficacyandbiomarkerresultsofsrk181alatenttgfb1inhibitorinantipd1resistantmetastaticccrccpatients AT yawenju 666safetyefficacyandbiomarkerresultsofsrk181alatenttgfb1inhibitorinantipd1resistantmetastaticccrccpatients AT susanhenry 666safetyefficacyandbiomarkerresultsofsrk181alatenttgfb1inhibitorinantipd1resistantmetastaticccrccpatients |